New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - After much heated debate, New Zealand's newly elected National Party has overturned the Pharmaceutical Management Agency's decision to decline funding for 12-month treatment of Roche's Herceptin (trastuzumab) for HER2-positive early breast cancer treatment